Showing results (321-330 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|July 27, 2025
Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trialL Gui, Z Xie, W Zhang, et al.
ESMO Open|June 2, 2025
Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settingsK Takagi, G Saito, H Tanaka, et al.
ESMO Open|June 3, 2025
Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RETA Ronaghy, E Crimini, V R Holla, et al.
ESMO Open|May 7, 2025
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDONS Peters, K S Oliner, A L'Hernault, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
ESMO Open|November 7, 2025
Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trialJ J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
ESMO Open|November 7, 2025
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancerE Borcoman, A Hervieu, C Cropet, et al.
ESMO Open|November 6, 2025
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortiumS F Haj Mohammad, H van der Pol, E Vrdoljak, et al.
ESMO Open|October 28, 2025
Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapyP Bossi, R Gili, S Calza, et al.
ESMO Open|October 24, 2025
Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancersK Muro, K Chin, S B Maron, et al.
Pageof 184